{"nctId":"NCT00404924","briefTitle":"ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures","startDateStruct":{"date":"2006-11"},"conditions":["Non-Small-Cell Lung Carcinoma"],"count":1140,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Best Supportive Care"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: ZD6474 (vandetanib)","Other: Best Supportive Care"]}],"interventions":[{"name":"ZD6474 (vandetanib)","otherNames":["ZACTIMA™"]},{"name":"Best Supportive Care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with Non-small cell lung cancer for which the standard cancer treatments of surgery, chemotherapy, radiation or other anticancer drugs are no longer appropriate treatments for you.\n\nExclusion Criteria:\n\n* Patients who have had standard cancer treatments of surgery, chemotherapy or other systemic anti-cancer therapy within 4 weeks before start of study therapy.\n* Three or more prior chemotherapy regimens.\n* Significant cardiovascular events.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"Median time (in months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria.\n\nThe categories for best objective response are CR, PR, stable disease (SD)\\>= 8 weeks, progressive disease (PD) or NE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"Disease control rate is defined as the number of patients who achieved disease control at 8 weeks following randomisation. Disease control at 8 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) \\>= 8 weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"24.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall Survival (OS) is defined as the time from date of randomization until death. Any blinded/unknown patient which have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie, their status must be known at the censored date and should not be lost to follow up or unknown).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"7.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration of Disease-related Symptoms (TDS) by Questionnaire - the Lung Cancer Subscale (LCS) a Selection of the FACT-L Focusing on Symptoms of Lung Cancer Plus Pain and Fatigue (LCS-PF)","description":"Time to deterioration in symptoms is defined as the interval from the date of randomization to the first assessment of 'worsened' with no visit assessment of 'improved' within the next 28 days. Where assessment is by a selection of questions from the Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) questionnaire.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":160,"n":619},"commonTop":["Diarrhoea","Rash","Decreased Appetite","Nausea","Hypertension"]}}}